LD50=5000 mg/kg (Orally in rats)
Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aripiprazole | The metabolism of Aripiprazole can be increased when combined with Felbamate. |
| Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be increased when combined with Felbamate. |
| Cilostazol | The serum concentration of Cilostazol can be increased when it is combined with Felbamate. |
| Buprenorphine | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Felbamate. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Felbamate. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Felbamate. |
| Hydrocodone | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Felbamate can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Felbamate may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Felbamate. |
| Mirtazapine | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Felbamate. |
| Orphenadrine | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Pramipexole | Felbamate may increase the sedative activities of Pramipexole. |
| Ropinirole | Felbamate may increase the sedative activities of Ropinirole. |
| Rotigotine | Felbamate may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Felbamate. |
| Sodium oxybate | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Felbamate. |
| Thalidomide | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Mefloquine | The therapeutic efficacy of Felbamate can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Felbamate can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Felbamate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Butalbital | The serum concentration of Butalbital can be increased when it is combined with Felbamate. |
| Pentobarbital | The serum concentration of Pentobarbital can be increased when it is combined with Felbamate. |
| Secobarbital | The serum concentration of Secobarbital can be increased when it is combined with Felbamate. |
| Methohexital | The serum concentration of Methohexital can be increased when it is combined with Felbamate. |
| Thiopental | The serum concentration of Thiopental can be increased when it is combined with Felbamate. |
| Thiamylal | The serum concentration of Thiamylal can be increased when it is combined with Felbamate. |
| Amobarbital | The serum concentration of Amobarbital can be increased when it is combined with Felbamate. |
| Hexobarbital | The serum concentration of Hexobarbital can be increased when it is combined with Felbamate. |
| Barbital | The serum concentration of Barbital can be increased when it is combined with Felbamate. |
| Barbexaclone | The serum concentration of Barbexaclone can be increased when it is combined with Felbamate. |
| Butabarbital | The serum concentration of Butabarbital can be increased when it is combined with Felbamate. |
| Phenytoin | The serum concentration of Phenytoin can be increased when it is combined with Felbamate. |
| Fosphenytoin | The serum concentration of Fosphenytoin can be increased when it is combined with Felbamate. |
| Topotecan | Felbamate may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Valproic acid | The serum concentration of Valproic acid can be increased when it is combined with Felbamate. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Felbamate. |
| Memantine | The risk or severity of adverse effects can be increased when Felbamate is combined with Memantine. |
| Carbamazepine | The serum concentration of Felbamate can be decreased when it is combined with Carbamazepine. |
| Ifosfamide | The metabolism of Ifosfamide can be increased when combined with Felbamate. |
| Perampanel | The metabolism of Perampanel can be increased when combined with Felbamate. |
| Warfarin | The metabolism of Warfarin can be increased when combined with Felbamate. |
| Acenocoumarol | The metabolism of Acenocoumarol can be increased when combined with Felbamate. |
| (R)-warfarin | The metabolism of (R)-warfarin can be increased when combined with Felbamate. |
| R,S-Warfarin alcohol | The metabolism of R,S-Warfarin alcohol can be increased when combined with Felbamate. |
| S,R-Warfarin alcohol | The metabolism of S,R-Warfarin alcohol can be increased when combined with Felbamate. |
| (S)-Warfarin | The metabolism of (S)-Warfarin can be increased when combined with Felbamate. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Felbamate. |
| Primidone | The serum concentration of Phenobarbital, an active metabolite of Primidone, can be increased when used in combination with Felbamate. |
| Methylphenobarbital | The serum concentration of Phenobarbital, an active metabolite of Methylphenobarbital, can be increased when used in combination with Felbamate. |
| Phenobarbital | The serum concentration of Phenobarbital, an active metabolite of Phenobarbital, can be increased when used in combination with Felbamate. |
| Ethanol | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Felbamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Felbamate. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Felbamate is combined with Fluvoxamine. |
| Duloxetine | The risk or severity of adverse effects can be increased when Felbamate is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Felbamate is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Felbamate is combined with Sibutramine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Felbamate is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Felbamate is combined with Dapoxetine. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Felbamate is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Felbamate is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Felbamate is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Felbamate is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Felbamate is combined with Alaproclate. |
| Escitalopram | The risk or severity of adverse effects can be increased when Felbamate is combined with Escitalopram. |
| Erlotinib | The serum concentration of Erlotinib can be decreased when it is combined with Felbamate. |
| Benzatropine | The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Felbamate. |
| Buclizine | The risk or severity of QTc prolongation can be increased when Buclizine is combined with Felbamate. |
| Hyoscyamine | The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Felbamate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Felbamate. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Felbamate. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Felbamate. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with Felbamate. |
| Desipramine | The risk or severity of CNS depression can be increased when Felbamate is combined with Desipramine. |
| Solifenacin | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Solifenacin. |
| Pizotifen | The risk or severity of CNS depression can be increased when Felbamate is combined with Pizotifen. |
| Trimebutine | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Trimebutine. |
| Dosulepin | The risk or severity of CNS depression can be increased when Felbamate is combined with Dosulepin. |
| Nicardipine | The metabolism of Felbamate can be decreased when combined with Nicardipine. |
| Clozapine | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Clozapine. |
| Zopiclone | The risk or severity of adverse effects can be increased when Felbamate is combined with Zopiclone. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Leuprolide. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Goserelin. |
| Erythromycin | The serum concentration of Felbamate can be increased when it is combined with Erythromycin. |
| Azithromycin | The metabolism of Azithromycin can be increased when combined with Felbamate. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Moxifloxacin. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Sulfisoxazole. |
| Diltiazem | The metabolism of Felbamate can be decreased when combined with Diltiazem. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Felbamate is combined with Nimodipine. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Felbamate. |
| Ciprofloxacin | The metabolism of Felbamate can be decreased when combined with Ciprofloxacin. |